echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > What are the adverse effects of producing generic drugs to curb the price rise of brand drugs? Mylan was the first

    What are the adverse effects of producing generic drugs to curb the price rise of brand drugs? Mylan was the first

    • Last Update: 2016-09-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit
    Source: medical geography on September 1, 2016, mylan Pharmaceutical (mylan) was pushed to the center of public opinion due to the 500% price increase of its adrenaline pen Epipen in the past seven years

    Epipen, used to treat anaphylactic shock, is an essential medicine box for families in Europe and America

    Since 2009, the price of Epipen has increased from less than $100 in two bottles to $608 (equivalent to RMB 4050) in May this year

    Nearly five times of the price increase has made the American people shout that they can't afford ordinary medicine

    At the same time, the share price of mylan pharmaceutical fell

    Double the drug price according to a previous survey report, in 2001, the initial price of Epipen (two packs) was only US $75.8, and then increased by about 3% - 4% every year

    After being purchased by mylan in 2008, the prices in 2008 and 2009 rose by 5% and 20% respectively, and then increased eight times in four years, all at 10%

    In November 2013, the price of Epipen increased by 15% again

    Until May this year, the price of Epipen was adjusted by 15% five times

    Not only has the price of Epipen skyrocketed, but the price of other products of mylan has also skyrocketed in recent years

    Some experts pointed out that 31 products of mylan have different price increases, of which 7 products have a price increase of more than 100% and 24 products have a price increase of more than 20%

    The biggest increase was ursodiol (54.2%), metoclopramide (44.4%) and dicycline (400%)

    In an interview with CNBC, Heather bresch, mylan's chief executive, said that there were many sales links in the company's Epipen, resulting in a huge difference between the factory price and the actual price of the product

    But people don't buy into that

    The rising CEO's salary, along with the rising drug price, is one of the factors that cause patients' dissatisfaction with the rising price event, as well as the rising salary of Meilan CEO Heather bresch in recent years

    According to fiercepharma, Heather bresch ranks sixth in the salary of CEO of global pharmaceutical companies (2015) with an annual salary of US $25.82 million (RMB 172 million)

    It is said that since taking office in 2012, Heather bresch's salary has increased from $2.453 million to $1.893 million, or 671%

    The corresponding is the rising drug prices since she took office

    Before the less competitive market, Epipen's biggest competitor was the adrenaline injection auvi-q of Sanofi

    In 2012, auvi-q, an adrenaline injection developed by Sanofi, was approved by the FDA for emergency treatment in the event of fatal allergic reactions in people with a history of allergies

    It is also the first compressed adrenaline automatic syringe, with its own voice guidance function, which can guide every step of the injection procedure of patients

    The launch of auvi-q challenges Epipen's market share for 25 years

    Auvi-q is popular with patients as soon as it comes into the market due to its own voice function and safer retraction of the needle

    The market position of Epipen in the past 25 years has been strongly shaken

    However, at the end of October 2015, Sanofi announced a recall of all products in the U.S

    and Canada markets due to insufficient dose of syringes to prevent more serious health and safety problems

    The position of "the biggest in the Jianghu" of adrenaline syringe was in danger

    Because of the mistake of competitors, Epipen took a breath

    Just a month after auvi-q exited the market, Meilan raised the price of Epipen again

    Using generic drugs to save people's grievances, the rising price makes Meilan earn a lot of money with one Epipen, but it has caused waves of resentment of the American people

    Although there is no regulatory regulation to control the price adjustment of mylan's drugs, the media's increasing attention in recent years has really put pressure on mylan

    So recently, in order to quell the price increase, mylan announced on August 29 that it would produce the generic drugs of Epipen, which have the same functions and ingredients, and the price of generic drugs would be reduced to half of the original brand drugs

    It is also the first time that pharmaceutical companies have made generic drugs of their own brand to ease the market resistance caused by the high price of brand drugs

    At the same time, Meilan also said that the price increase is more used for medical sales, commercial insurance, supply chain and other links of expenditure

    Mylan said in a new generic product description that the company has been working to help patients pay $0 for Epipen syringes with commercial insurance

    In fact, in 2015, 80% of patients did enjoy such benefits

    Due to the change of the medical insurance environment, the patient's medical health insurance and payment standards have changed, which leads to the improvement of the part of the medical expenses paid by the patient

    As a result, the Epipen generic, which costs 50% of the brand drug, was launched for $300 to ease patients' concerns about high drug costs

    However, this time, mylan's behavior can only be called "mending the past"

    Now mylan is in a similar crisis with Turing pharmaceuticals

    "When it comes to human health, pharmaceutical companies should realize that it's not just about earnings, it's about human health," wrote one columnist Once again, the social responsibility of pharmaceutical enterprises has been questioned by the society

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.